CSL.XASX Overview
Upcoming Projects (CSL.XASX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CSL.XASX)
-
A third look: Discussing the potential of HEMGENIX(etranacogene dezaparvovec-drlb), the first FDA-approved gene therapy for patients with hemophilia B, based on the ongoing HOPE-B trial
Ticker: CSL.XASX
Executed On: Jan 12, 2023 at 05:00 PM EST -
A second look: Discussing the potential of HEMGENIX(etranacogene dezaparvovec-drlb), the first FDA-approved gene therapy for patients with hemophilia B, based on the ongoing HOPE-B trial
Tickers: CSL.XASX, QURE
Executed On: Dec 16, 2022 at 10:30 AM EST -
Discussing the potential of HEMGENIX(etranacogene dezaparvovec-drlb), the first FDA-approved gene therapy for patients with hemophilia B, based on the ongoing HOPE-B trial
Tickers: CSL.XASX, QURE
Executed On: Dec 09, 2022 at 02:15 PM EST
Upcoming & Overdue Catalysts (CSL.XASX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CSL.XASX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
